Physician profile
Robert Jones
NPI 1487668638
$1,134.39
in general payments reported to CMS, 2019-2025
14 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.31 · 2021: $66.55 · 2022: $177 · 2023: $249 · 2024: $374 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.54 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $297.94 | 2021-2025 | |
| Lilly USA, LLC | $69.20 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $42.28 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $41.02 | 2024 | Voquezna |
| Almatica Pharma LLC | $35.77 | 2023-2025 | Loreev Xr |
| Novo Nordisk INC | $34.18 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.07 | 2020-2021 | |
| Axsome Therapeutics, INC. | $21.16 | 2025 | Sunosi |
| Pfizer INC. | $19.56 | 2025 | |
| Eagle Pharmaceuticals, INC. | $16.68 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.68 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $11.82 | 2022 | |
| Clarus Therapeutics INC. | $9.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.